Compass Therapeutics (CMPX) Other Accumulated Expenses (2019 - 2026)
Compass Therapeutics recorded quarterly Other Accumulated Expenses of $708000.0 in Q1 2026, up 46.28% quarter-over-quarter from $484000.0 in Q4 2025, and up 158.39% year-over-year from $274000.0 in Q1 2025.
Compass Therapeutics' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $708000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 158.39% year-over-year to $708000.0; the TTM figure through Mar 2026 stood at $708000.0 (up 158.39% YoY), while the FY2025 annual figure was $484000.0, down 22.06% from the prior year.
- Other Accumulated Expenses came in at $708000.0 for Q1 2026 at Compass Therapeutics, up from $484000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.5 million in Q1 2022 to a low of $88000.0 in Q3 2022.
- A 5-year average of $372470.6 and a median of $281000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses surged 481.35% in 2022 and plunged 90.65% in 2023, its largest moves.
- Compass Therapeutics' Other Accumulated Expenses stood at $96000.0 in 2022, then surged by 150.0% to $240000.0 in 2023, then soared by 158.75% to $621000.0 in 2024, then slipped by 22.06% to $484000.0 in 2025, then jumped by 46.28% to $708000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $708000.0, $484000.0, and $141000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 708,000.00 |
| Dec 31, 2025 | 484,000.00 |
| Sep 30, 2025 | 141,000.00 |
| Jun 30, 2025 | 384,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | 621,000.00 |
| Sep 30, 2024 | 167,000.00 |
| Jun 30, 2024 | 308,000.00 |
| Mar 31, 2024 | 281,000.00 |
| Dec 31, 2023 | 240,000.00 |
| Sep 30, 2023 | 391,000.00 |
| Jun 30, 2023 | 255,000.00 |
| Mar 31, 2023 | 137,000.00 |
| Dec 31, 2022 | 96,000.00 |
| Sep 30, 2022 | 88,000.00 |
| Jun 30, 2022 | 292,000.00 |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 470,000.00 |
| Sep 30, 2021 | 70,000.00 |
| Mar 31, 2021 | 252,000.00 |
| Dec 31, 2020 | 383,000.00 |
| Sep 30, 2020 | 220,000.00 |
| Jun 30, 2020 | 223,000.00 |
| Dec 31, 2019 | 249,000.00 |